Immunogenicity of Short-Course, High-Dose Hepatitis B Vaccination in Patients with Chronic Kidney Disease - Shanxi Province, China, 2019-2020.

IF 4.3 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

中国疾病预防控制中心周报 Pub Date : 2024-12-13 DOI:10.46234/ccdcw2024.264

Linying Gao, Xufeng Cui, Xinyuan Mo, Zhaoyue Men, Xiuyang Xu, Tian Yao, Jianmin Wang, Hongting Liu, Hongping Guo, Guowei Chai, Liming Liu, Fuzhen Wang, Xiaofeng Liang, Suping Wang, Yongliang Feng

{"title":"Immunogenicity of Short-Course, High-Dose Hepatitis B Vaccination in Patients with Chronic Kidney Disease - Shanxi Province, China, 2019-2020.","authors":"Linying Gao, Xufeng Cui, Xinyuan Mo, Zhaoyue Men, Xiuyang Xu, Tian Yao, Jianmin Wang, Hongting Liu, Hongping Guo, Guowei Chai, Liming Liu, Fuzhen Wang, Xiaofeng Liang, Suping Wang, Yongliang Feng","doi":"10.46234/ccdcw2024.264","DOIUrl":null,"url":null,"abstract":"What is already known about this topic?: As one of the populations at high risk of hepatitis B virus (HBV) infection, patients with chronic kidney disease (CKD) require rapid and effective development of hepatitis B surface antibodies (anti-HBs).What is added by this report?: The short-course, high-dose regimen of hepatitis B vaccination rapidly induced comparable immunological responses to the routine regimen, achieving a seroconversion rate of 88.5%, a high-response rate of 64.1%, and anti-HBs geometric mean concentrations of 824.1 mIU/mL.What are the implications for public health practice?: The short-course, high-dose regimen represents an effective rapid immunization strategy for CKD patients, particularly when administered prior to immunosuppressive therapy. This study provides compelling evidence for optimizing immunization protocols in the CKD population.","PeriodicalId":69039,"journal":{"name":"中国疾病预防控制中心周报","volume":"6 50","pages":"1331-1336"},"PeriodicalIF":4.3000,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11673178/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国疾病预防控制中心周报","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.46234/ccdcw2024.264","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

What is already known about this topic?: As one of the populations at high risk of hepatitis B virus (HBV) infection, patients with chronic kidney disease (CKD) require rapid and effective development of hepatitis B surface antibodies (anti-HBs).

What is added by this report?: The short-course, high-dose regimen of hepatitis B vaccination rapidly induced comparable immunological responses to the routine regimen, achieving a seroconversion rate of 88.5%, a high-response rate of 64.1%, and anti-HBs geometric mean concentrations of 824.1 mIU/mL.

What are the implications for public health practice?: The short-course, high-dose regimen represents an effective rapid immunization strategy for CKD patients, particularly when administered prior to immunosuppressive therapy. This study provides compelling evidence for optimizing immunization protocols in the CKD population.

查看原文本刊更多论文

慢性肾脏疾病患者短疗程高剂量乙型肝炎疫苗免疫原性研究——山西省，中国，2019-2020。

本主题的已知信息：作为乙型肝炎病毒（HBV）感染的高危人群之一，慢性肾脏病（CKD）患者需要快速有效地发展乙型肝炎表面抗体（抗-HBs）：短程大剂量乙肝疫苗接种方案能迅速诱导出与常规方案相当的免疫反应，实现了88.5%的血清转换率、64.1%的高应答率和824.1 mIU/mL的抗-HBs几何平均浓度：短程、大剂量方案是针对慢性肾脏病患者的一种有效的快速免疫策略，尤其是在免疫抑制治疗前进行免疫接种时。这项研究为优化 CKD 患者的免疫方案提供了令人信服的证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中国疾病预防控制中心周报

CiteScore

5.90

自引率

0.00%

发文量